How Much Does Rezdiffra (Resmetirom) Cost in Virginia in 2026?

Virginia Retail Pricing for Rezdiffra in 2026

Rezdiffra's wholesale acquisition cost (WAC) sits at roughly $3,500 per month, and Virginia retail pharmacies generally mirror that figure for uninsured or cash-pay patients. This price point reflects Madrigal Pharmaceuticals' positioning of resmetirom as the first and only FDA-approved therapy targeting the thyroid hormone receptor beta (THR-β) pathway in metabolic dysfunction-associated steatohepatitis (MASH).

How the Price Compares Nationally

Virginia's average cash-pay cost tracks closely with the national median. Because Rezdiffra launched nationally with a uniform WAC, geographic variation is minimal. The $3,500 monthly figure represents the pre-insurance, pre-discount sticker price. Actual out-of-pocket spending depends on insurance tier placement, copay card eligibility, and whether the patient fills at a specialty or retail pharmacy.

Specialty Pharmacy vs. Retail Fill

Many Virginia insurers route Rezdiffra through specialty pharmacy channels. Specialty pharmacies often coordinate benefits verification and prior authorization on behalf of the patient, which can speed access. CVS Specialty, Accredo, and AllianceRx Walgreens Prime all distribute Rezdiffra in Virginia. Retail fills remain possible but may require the prescriber to submit PA documentation separately. The FDA-approved prescribing information specifies two dose strengths (80 mg and 100 mg tablets), and the monthly cost applies to either strength.

Virginia Medicaid Coverage

Virginia Medicaid covers Rezdiffra with prior authorization. The PA process typically requires documentation of biopsy-confirmed or non-invasive-test-confirmed MASH with stage F2 or F3 hepatic fibrosis, consistent with the FDA-approved indication [1].

PA Requirements and Documentation

Prescribers submitting PA requests to Virginia Medicaid should expect to provide the following: a confirmed MASH diagnosis, fibrosis staging (via liver biopsy, FibroScan with a score ≥ 8.0 kPa, or validated serum biomarker panels such as FIB-4 or ELF), and documentation that the patient does not have decompensated cirrhosis (Child-Pugh B or C). The MAESTRO-NASH trial enrolled patients with F1B through F3 fibrosis, though the FDA label restricts the indication to F2-F3 [2].

Approval Turnaround

PA decisions from Virginia Medicaid generally arrive within 24 to 72 hours for standard requests. Urgent or expedited requests may be reviewed within 24 hours. If denied, patients and prescribers can appeal through the Virginia Department of Medical Assistance Services (DMAS) fair hearing process. Denial rates for novel hepatology drugs in Virginia Medicaid have historically been higher during the first 12 months post-launch, then stabilize as formulary committees accumulate real-world utilization data.

Commercial Insurance Coverage in Virginia

Most large commercial insurers operating in Virginia, including Anthem Blue Cross Blue Shield, Aetna, UnitedHealthcare, and Cigna, have added Rezdiffra to their formularies as a specialty-tier drug. Placement on a specialty tier typically means higher copays or coinsurance (often 25% to 33% of the drug cost) before any manufacturer support is applied.

Step Therapy and Utilization Management

Some Virginia plans require step therapy before approving Rezdiffra. This may include documentation of lifestyle interventions (diet modification, exercise, weight management) and, in some cases, prior use of vitamin E (800 IU/day) or pioglitazone for MASH, both of which have shown modest histological benefit in the PIVENS trial (N=247) [3]. Step therapy requirements vary by plan, so patients should request a coverage determination from their insurer before assuming Rezdiffra will be denied.

Employer-Sponsored Plans

Self-insured employer plans in Virginia (which cover the majority of commercially insured workers) set their own formulary rules. These plans are regulated under federal ERISA law rather than Virginia state insurance mandates. Coverage decisions for Rezdiffra on self-insured plans depend on the pharmacy benefit manager (PBM) contract, and patients may need to work directly with their employer's benefits team if a standard PA is denied.

The Madrigal Pharmaceuticals Savings Card

Madrigal offers a co-pay assistance program for commercially insured patients that can reduce monthly out-of-pocket costs to as little as $0 for eligible individuals. The card applies at the point of sale and covers the difference between the patient's copay or coinsurance and the program's floor (often $0 to $35 per fill).

Eligibility Criteria

The savings card is available to patients with commercial insurance. It excludes patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state-funded healthcare program. This exclusion follows standard pharmaceutical co-pay card rules under the federal Anti-Kickback Statute, which prohibits manufacturer subsidies for government-insured patients. Virginia residents with commercial coverage can enroll through the Madrigal website or through their specialty pharmacy.

Annual Cap

Most manufacturer co-pay cards carry an annual benefit maximum. For Rezdiffra, the annual cap has historically been set in the range of $15,000 to $20,000. At $3,500/month list price, patients with high coinsurance (e.g., 30% = $1,050/month) could exhaust the annual benefit within 14 to 19 months. Patients should confirm the current cap at the time of enrollment, as Madrigal may adjust these figures annually.

Compounded Resmetirom in Virginia

Licensed 503A compounding pharmacies in Virginia can legally prepare compounded resmetirom formulations pursuant to a valid patient-specific prescription. Virginia follows federal guidance under the Drug Quality and Security Act (DQSA) [4], which permits 503A pharmacies to compound drugs that are commercially available only when certain conditions are met (e.g., a clinically meaningful difference in formulation for a specific patient need).

Cost Considerations

Compounded resmetirom pricing varies by pharmacy but can be significantly lower than the branded Rezdiffra product. Some 503A pharmacies in Virginia advertise compounded resmetirom at a fraction of the branded cost. Patients considering a compounded option should verify that the compounding pharmacy holds a valid Virginia Board of Pharmacy license and sources pharmaceutical-grade active ingredients.

Quality and Bioequivalence

Compounded medications are not FDA-approved and do not undergo the same bioequivalence testing as commercially manufactured drugs. The FDA has repeatedly noted [5] that compounded products may vary in potency, purity, and stability. For a drug like resmetirom, where precise THR-β agonism drives efficacy, dose consistency matters. The MAESTRO-NASH phase 3 trial demonstrated that the 100 mg dose achieved MASH resolution in 25.9% of patients vs. 9.7% for placebo at 52 weeks [2], a result tied to the specific manufactured formulation.

Clinical Value Behind the Price

Rezdiffra's $3,500/month cost reflects its status as a first-in-class therapy. Before its March 2024 FDA approval, no drug carried an FDA indication for MASH. The clinical evidence supporting this price comes primarily from the MAESTRO-NASH program.

MAESTRO-NASH Efficacy Data

In the MAESTRO-NASH trial (N=966), resmetirom 100 mg achieved the dual primary endpoints at 52 weeks: MASH resolution without worsening fibrosis (25.9% vs. 9.7% placebo) and fibrosis improvement by at least one stage without NASH worsening (24.2% vs. 14.2% placebo) [2]. The 80 mg dose also showed significant fibrosis improvement (25.9% vs. 14.2%) [2]. These results led to accelerated FDA approval, with continued approval contingent on confirmatory benefit in ongoing studies.

Liver-Specific Biomarker Effects

Resmetirom reduced LDL cholesterol by approximately 14% to 16% and lowered hepatic fat fraction (measured by MRI-PDFF) by a median of roughly 45% at 52 weeks in MAESTRO-NASH [6]. Liver enzyme improvements were also observed: ALT levels decreased by an average of 20 to 25 U/L from baseline in treated patients. These biomarker shifts align with the drug's mechanism as a selective THR-β agonist, which increases hepatic lipid metabolism and reduces lipotoxicity (Harrison et al., NEJM 2024) [2].

Safety Profile and Monitoring Costs

The most common adverse events in MAESTRO-NASH were diarrhea (27% vs. 19% placebo) and nausea (20% vs. 12% placebo) [2]. Resmetirom carries FDA-label warnings for drug-induced liver injury, and patients require periodic liver function monitoring [1]. In Virginia, a comprehensive metabolic panel (CMP) costs $15 to $40 at most labs, adding a minor but necessary expense to the overall cost of therapy.

Telehealth Access in Virginia

Virginia permits telehealth prescribing of Rezdiffra. Following the state's expansion of telehealth regulations during and after the COVID-19 pandemic, Virginia-licensed prescribers can evaluate patients via synchronous audio-video visits and issue prescriptions for controlled and non-controlled medications, including resmetirom. The Virginia Board of Medicine requires that the prescriber establish a bona fide provider-patient relationship, which can occur via telehealth under Virginia Code § 54.1-3303.

Practical Workflow

A typical Virginia telehealth workflow for Rezdiffra involves an initial consultation (reviewing MASH diagnosis, fibrosis stage, contraindications, and concurrent medications), followed by e-prescribing to a specialty or compounding pharmacy. Lab monitoring (liver function tests at baseline, 3 months, and every 6 to 12 months thereafter per the FDA label [1]) can be completed at any Virginia lab, with results forwarded to the telehealth provider.

Cost-Reduction Strategies for Virginia Patients

Patients in Virginia have several options to reduce out-of-pocket costs for Rezdiffra beyond the Madrigal savings card.

Patient Assistance Programs

Madrigal Pharmaceuticals offers a patient assistance program (PAP) for uninsured or underinsured patients who meet income eligibility criteria (typically ≤ 400% of the federal poverty level). PAPs provide the branded drug at no cost. Virginia residents can apply through Madrigal's website or through the specialty pharmacy handling their prescription.

Foundation Support

Independent charitable foundations, such as the HealthWell Foundation and Patient Access Network (PAN) Foundation, periodically open disease-specific funds that cover copays for liver disease therapies. Availability of these funds fluctuates, and Virginia patients should check quarterly for open enrollment periods. These foundations can assist Medicare patients who are ineligible for manufacturer co-pay cards.

Formulary Exception Requests

If a Virginia insurer places Rezdiffra on a non-preferred tier or excludes it entirely, the prescriber can submit a formulary exception request citing clinical necessity. Supporting documentation should include the patient's fibrosis stage, evidence of disease progression, failure or intolerance of off-label alternatives (vitamin E, pioglitazone), and the MAESTRO-NASH efficacy data. The AASLD 2023 Practice Guidance on NAFLD/MASH [7] provides clinical context that supports resmetirom use in patients with significant fibrosis.

340B Program Eligibility

Virginia has over 100 healthcare entities participating in the federal 340B Drug Pricing Program [8], including federally qualified health centers (FQHCs) and certain hospital outpatient departments. Eligible patients receiving care at 340B-covered entities may access Rezdiffra at a significantly reduced cost. The 340B discount on specialty drugs can reach 25% to 50% off WAC.

Drug Interactions and Monitoring in Virginia

Resmetirom interacts with several commonly prescribed medications. The FDA prescribing information [1] notes that resmetirom may reduce the efficacy of hormonal contraceptives by increasing sex hormone-binding globulin (SHBG) and altering thyroid hormone metabolism. Patients on statins should also be monitored, as resmetirom's effect on hepatic lipid pathways can amplify statin-related LDL reduction. In MAESTRO-NASH, patients on background statin therapy experienced an additional 7% to 10% LDL reduction beyond their statin baseline [2].

Virginia prescribers should also check for interactions with warfarin (resmetirom may increase INR), levothyroxine (potential for additive thyroid-axis effects), and strong CYP2C8 inhibitors (e.g., gemfibrozil), which can increase resmetirom exposure. The MAESTRO-NAFLD-1 open-label extension study [9] reported no unexpected safety signals through 52 weeks of extended dosing, but real-world polypharmacy in the Virginia patient population warrants careful medication reconciliation.

MASH Prevalence in Virginia

An estimated 1.5 to 2 million Virginia adults have non-alcoholic fatty liver disease (NAFLD), and roughly 20% to 30% of those (300,000 to 600,000) may have progressed to MASH, based on national prevalence data extrapolated from the National Health and Nutrition Examination Survey (NHANES) [10]. Virginia's obesity rate of approximately 35% (per CDC BRFSS 2023 data) [11] and high prevalence of type 2 diabetes (approximately 11% of adults) contribute to a substantial at-risk population.

Fibrosis Stage Distribution

Among patients with confirmed MASH, roughly 20% to 25% have stage F2 or F3 fibrosis, the population eligible for Rezdiffra per its FDA label [1]. Applied to Virginia's estimated MASH population, this suggests 60,000 to 150,000 Virginians could be candidates for resmetirom therapy. Not all will be diagnosed; MASH remains underdiagnosed nationally, with the AASLD [7] noting that fewer than 5% of patients with significant fibrosis have been identified in primary care settings.